Ironwood Pharmaceuticals Stock Forecast, Price & News

Ironwood Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IRWD stock has increased by 14.1% and is now trading at $11.98.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Ironwood Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Ironwood Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ironwood Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ironwood Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.14 by $0.09. The biotechnology company had revenue of $103.50 million for the quarter, compared to analyst estimates of $96.08 million. Ironwood Pharmaceuticals had a net margin of 27.77% and a negative return on equity of 240.80%. Ironwood Pharmaceuticals's revenue for the quarter was down 21.1% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS.
View Ironwood Pharmaceuticals' earnings history.

Ironwood Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-385 million, compared to the consensus revenue estimate of $369.15 million.

5 brokerages have issued 12-month target prices for Ironwood Pharmaceuticals' shares. Their forecasts range from $9.00 to $14.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $11.60 in the next twelve months. This suggests that the stock has a possible downside of 3.2%.
View analysts' price targets for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil Co. (ATH.TO) (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.81%), State Street Corp (4.99%), Camber Capital Management LP (4.53%), UBS Asset Management Americas Inc. (2.16%), Charles Schwab Investment Management Inc. (0.71%) and Peregrine Capital Management LLC (0.70%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt.
View institutional ownership trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., BlackRock Inc., State Street Corp, AQR Capital Management LLC, Peregrine Capital Management LLC, Weld Capital Management LLC, Squarepoint Ops LLC, and Federated Hermes Inc.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Julie Mchugh, Mark G Currie, and Thomas A Mccourt.
View insider buying and selling activity for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Camber Capital Management LP, ExodusPoint Capital Management LP, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ, Jennison Associates LLC, ClariVest Asset Management LLC, and Principal Financial Group Inc..
View insider buying and selling activity for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $11.98.

Ironwood Pharmaceuticals has a market capitalization of $1.92 billion and generates $428.41 million in revenue each year. The biotechnology company earns $21.50 million in net income (profit) each year or $0.55 on an earnings per share basis. Ironwood Pharmaceuticals employs 317 workers across the globe.

The official website for Ironwood Pharmaceuticals is www.ironwoodpharma.com.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]